This is a fully human IgG1 monoclonal antibody using the same sequences as the therapeutic antibody golimumab. It is derived from immunizing genetically engineered mice with human tumor necrosis factor alpha (TNFa). Elevated TNFa levels are associated with chronic inflammation. Golimumab binds and inhibits both soluble and transmembrane hTNFa, thereby preventing its interaction with receptors. This inhibition impedes leukocyte infiltration by blocking cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, as well as suppressing pro-inflammatory cytokine secretion including IL6, IL8, G-CSF and GM-CSF in vitro. Therefore, golimumab is indicated for use in adults as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), as a single agent in patients with active ankylosing spondylitis (AS), and also as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.